GH Research
GHRS

$7.54

3.33%

Market Cap: $392M

About: GH Research PLC is a clinical-stage biopharmaceutical company dedicated to transforming the treatment of psychiatric and neurological disorders. The company is focused on developing novel and proprietary Mebufotenin 5-Methoxy-N, N-Dimethyltryptamine, or 5-MeO-DMT, therapies for the treatment of patients with Treatment-Resistant Depression, or TRD.

Employees: 49

0

Funds holding %

of 6,710 funds

0

Analysts bullish %

of 3 analysts

Fund manager confidence

Based on 2024 Q2 SEC filings by fund managers ($100M+ AUM)

3,135% more call options, than puts

Call options by funds: $744K | Put options by funds: $23K

11% more capital invested

Capital invested by funds: $319M [Q1] → $355M (+$36.2M) [Q2]

1.05% more ownership

Funds ownership: 57.43% [Q1] → 58.48% (+1.05%) [Q2]

0% more funds holding in top 10

Funds holding in top 10: 2 [Q1] → 2 (+0) [Q2]

13% less funds holding

Funds holding: 32 [Q1] → 28 (-4) [Q2]

13% less repeat investments, than reductions

Existing positions increased: 7 | Existing positions reduced: 8

67% less first-time investments, than exits

New positions opened: 2 | Existing positions closed: 6

See Fund Rankings

Research analyst outlook

3 Wall Street Analysts provided 1 year price targets over the past 3 months

Low target

$39

417%

upside

Avg. target

$40

426%

upside

High target

$40

431%

upside

3 analyst ratings

3 positive

100%

0 neutral

0%

0 negative

0%

HC Wainwright & Co. Patrick Trucchio 31% 1-year accuracy 40 / 127 met price target	431%upside $40	Buy Reiterated	5 Sept 2024
JMP Securities Jason Butler 49% 1-year accuracy 19 / 39 met price target	417%upside $39	Market Outperform Reiterated	4 Sept 2024
HC Wainwright & Co. Patrick Trucchio 31% 1-year accuracy 40 / 127 met price target	431%upside $40	Buy Reiterated	31 Jul 2024

See Analyst Rankings

Financial journalist opinion

Based on 4 articles about GHRS published over the past 30 days

Zacks Investment Research

GH Research (GHRS) Moves to Buy: Rationale Behind the Upgrade

GH Research (GHRS) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

GH Research (GHRS) Moves to Buy: Rationale Behind the Upgrade

Zacks Investment Research

After Plunging -18.19% in 4 Weeks, Here's Why the Trend Might Reverse for GH Research (GHRS)

GH Research (GHRS) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combined with strong agreement among Wall Street analysts in revising earnings estimates higher, indicates a potential trend reversal for the stock in the near term.

After Plunging -18.19% in 4 Weeks, Here's Why the Trend Might Reverse for GH Research (GHRS)

GH Research Reports Second Quarter 2024 Financial Results and Provides Business Updates

DUBLIN, Sept. 03, 2024 (GLOBE NEWSWIRE) -- GH Research PLC (Nasdaq: GHRS), a clinical-stage biopharmaceutical company dedicated to transforming the treatment of psychiatric and neurological disorders, today reported financial results for the second quarter ended June 30, 2024, and provided updates on its business.

GH Research Reports Second Quarter 2024 Financial Results and Provides Business Updates

GH Research Announces Appointment of Dr. Velichka “Villy” Valcheva to Chief Executive Officer

DUBLIN, Ireland, Sept. 03, 2024 (GLOBE NEWSWIRE) -- GH Research PLC (Nasdaq: GHRS), a clinical-stage biopharmaceutical company dedicated to transforming the treatment of psychiatric and neurological disorders, today announced the promotion of Dr. Velichka “Villy” Valcheva, MD, MSc. to Chief Executive Officer of the Company. Dr. Valcheva succeeds PD Dr. med. Theis Terwey, co-founder of GH Research.

GH Research Announces Appointment of Dr. Velichka “Villy” Valcheva to Chief Executive Officer

3 Psychedelic Stocks to Ride to the Moon and Beyond

The value of the psychedelic market is expected to approximately triple over the next few years. While not a large market in absolute terms, that growth potential will create many winning stocks.

3 Psychedelic Stocks to Ride to the Moon and Beyond

Zacks Investment Research

Recent Price Trend in GH Research (GHRS) is Your Friend, Here's Why

GH Research (GHRS) could be a great choice for investors looking to make a profit from fundamentally strong stocks that are currently on the move. It is one of the several stocks that made it through our "Recent Price Strength" screen.

Recent Price Trend in GH Research (GHRS) is Your Friend, Here's Why

Zacks Investment Research

Wall Street Analysts Predict a 166.89% Upside in GH Research (GHRS): Here's What You Should Know

The average of price targets set by Wall Street analysts indicates a potential upside of 166.9% in GH Research (GHRS). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.

Wall Street Analysts Predict a 166.89% Upside in GH Research (GHRS): Here's What You Should Know

GH Research Reports First Quarter 2024 Financial Results and Provides Business Updates

DUBLIN, Ireland, May 03, 2024 (GLOBE NEWSWIRE) -- GH Research PLC (Nasdaq: GHRS), a clinical-stage biopharmaceutical company dedicated to transforming the treatment of psychiatric and neurological disorders, today reported financial results for the first quarter ended March 31, 2024, and provided updates on its business.

GH Research Reports First Quarter 2024 Financial Results and Provides Business Updates

Zacks Investment Research

How Much Upside is Left in GH Research PLC (GHRS)? Wall Street Analysts Think 321.28%

The average of price targets set by Wall Street analysts indicates a potential upside of 321.3% in GH Research PLC (GHRS). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.

How Much Upside is Left in GH Research PLC (GHRS)? Wall Street Analysts Think 321.28%

GH Research Reports Full Year 2023 Financial Results and Provides Business Updates

DUBLIN, Ireland, Feb. 29, 2024 (GLOBE NEWSWIRE) -- GH Research PLC (Nasdaq: GHRS), a clinical-stage biopharmaceutical company dedicated to transforming the treatment of psychiatric and neurological disorders, today reported financial results for the year ended December 31, 2023, and provided updates on its business.

GH Research Reports Full Year 2023 Financial Results and Provides Business Updates

See News Rankings